I have to admit, aside from their incompetence at actually running the company and generating revenue and profits, management has learned to play the game by announcing positive data as they disappoint on performance.
Non-GAAP earnings were .46; but yes, a huge miss on earnings and revenues. Hard to believe they are continuing to lose market share to Victrelis, but there you have it. Actually taking a charge for excess Incivek inventory and guiding lower on 2012 revenues. Let's hope they are smart enough to use this Alios data to sell the company; otherwise it's a no-hoper.